Not financial advice. MarketPicks.ai is an impersonal research tool. AI output can be wrong. Investing involves risk of loss. Do your own research and consult a licensed professional. Full disclaimer.
SEC Form 4 · open-market trades
When a CEO, director or 10% owner buys or sells their own company's stock on the open market, they must file a Form 4 with the SEC within two business days. Every one of those trades filed since 2026-10-22 is here, updated hourly. Buys by several insiders at once (cluster buys) are the ones investors watch most.
Trades
531
Insider buys
145
Buy value
$33.69M
Cluster buys (30d)
8
Rapport Therapeutics, Inc.
5 insiders · 6 buys · latest 2026-10-23
Sanchez Ramiro, Paul Steven M, Maraganore John, Young Wendy B.
CITY HOLDING CO
4 insiders · 4 buys · latest 2026-10-23
Fisher Robert D, Strong-Treister Diane W, Hoyer James A, Reyes Javier A
Rent the Runway, Inc.
3 insiders · 3 buys · latest 2026-10-23
Nexus Capital Management LP, STORY3 Capital Partners, LLC, CHS US Investments LLC
NXG NextGen Infrastructure Income Fund
2 insiders · 2 buys · latest 2026-10-23
Swank Jerry V, Nelson Blake
BNY MELLON STRATEGIC MUNICIPALS, INC.
2 insiders · 3 buys · latest 2026-10-22
Saba Capital Management, L.P., Bank Of America Corp /De/
BNY MELLON STRATEGIC MUNICIPAL BOND FUND, INC.
2 insiders · 3 buys · latest 2026-10-22
Saba Capital Management, L.P., Bank Of America Corp /De/
U S GLOBAL INVESTORS INC
2 insiders · 2 buys · latest 2026-10-22
Gator Capital Management, LLC, Pilecki Derek Steven
Nuveen Municipal Credit Opportunities Fund
2 insiders · 3 buys · latest 2026-10-22
Jones Nathaniel T., Bank Of America Corp /De/
Showing RAPP. Clear · Open RAPP analysis
| Filed | Ticker | Insider | Title | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|---|---|
| 2026-10-23 | RAPP Rapport Therapeutics, Inc. | Sanchez Ramiro | Director | BUY | 3,600 | $27.35 | $98K | SEC filing |
| 2026-10-23 | RAPP Rapport Therapeutics, Inc. | Ceesay Abraham | Chief Executive Officer | SELL | 2,210 | $29.16 | $64K | SEC filing |
| 2026-10-22 | RAPP Rapport Therapeutics, Inc. | Paul Steven M | Director | BUY | 35,714 | $27.28 | $974K | SEC filing |
| 2026-10-22 | RAPP Rapport Therapeutics, Inc. | Maraganore John | Director | BUY | 8,239 | $26.38 | $217K | SEC filing |
| 2026-10-22 | RAPP Rapport Therapeutics, Inc. | Young Wendy B. | Director | BUY | 3,789 | $26.39 | $100K | SEC filing |
| 2026-10-22 | RAPP Rapport Therapeutics, Inc. | Silva Paul M | Director | BUY | 3,680 | $27.07 | $100K | SEC filing |
| 2026-10-22 | RAPP Rapport Therapeutics, Inc. | Maraganore John | Director | BUY | 1,172 | $26.92 | $32K | SEC filing |
Source: SEC EDGAR Form 4 filings (open-market purchases and sales only; option exercises, gifts and grants excluded). Research only, not investment advice.